Hoth Therapeutics Faces Delisting Concerns

Ticker: HOTH · Form: 8-K · Filed: 2025-05-16T00:00:00.000Z

Sentiment: bearish

Topics: delisting, compliance, regulatory

TL;DR

Hoth Therapeutics might get delisted - big trouble ahead.

AI Summary

Hoth Therapeutics, Inc. filed an 8-K on May 16, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The filing indicates potential issues with maintaining its listing on the stock exchange.

Why It Matters

This filing signals potential financial distress or non-compliance with exchange rules, which could lead to the company's stock being removed from trading.

Risk Assessment

Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.

Key Players & Entities

Hoth Therapeutics, Inc. (company) — Registrant
May 13, 2025 (date) — Date of earliest event reported
May 16, 2025 (date) — Date of Report
Nevada (jurisdiction) — State of incorporation
001-38803 (identifier) — Commission File Number
82-1553794 (identifier) — I. R. S. Employer Identification No.
1177 Avenue of the Americas, 5th Floor, Suite 5066 New York, NY 10036 (address) — Address of principal executive offices
(646) 756-2997 (phone_number) — Registrant's telephone number

FAQ

What specific listing rule or standard has Hoth Therapeutics, Inc. failed to satisfy?

The filing does not specify the exact rule or standard that Hoth Therapeutics, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is May 13, 2025.

What is the company's state of incorporation?

Hoth Therapeutics, Inc. is incorporated in Nevada.

What is the company's principal executive office address?

The principal executive offices are located at 1177 Avenue of the Americas, 5th Floor, Suite 5066, New York, NY 10036.

What is the purpose of this Form 8-K filing?

This Form 8-K is filed to report a notice of delisting or failure to satisfy a continued listing rule or standard.

From the Filing

0001213900-25-044894.txt : 20250516 0001213900-25-044894.hdr.sgml : 20250516 20250516161508 ACCESSION NUMBER: 0001213900-25-044894 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250513 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20250516 DATE AS OF CHANGE: 20250516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 25959422 BUSINESS ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: (646)756-2997 MAIL ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 8-K 1 ea0242374-8k_hoth.htm CURRENT REPORT false 0001711786 0001711786 2025-05-13 2025-05-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported) May 13, 2025   Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter)   Nevada   001-38803   82-1553794 (State or other jurisdiction of incorporation)   (Commission File Number)   (I. R. S. Employer Identification No.)   1177 Avenue of the Americas , 5th Floor , Suite 5066 New York , NY 10036 (Address of principal executive offices, including ZIP code)   ( 646 ) 756-2997 (Registrant’s telephone number, including area code)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   HOTH   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company  ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐               Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.   On May 13, 2025, Hoth Therapeutics, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 555